Jean-François Rax

Anagenesis Biotechnologies SAS operates as a preclinical-stage stem cell-based company. It focuses on developing novel treatments for genetic and age-related muscle degenerative diseases with unmet medical needs. The firm offers cell therapy for genetic diseases and pharmacological drugs for genetic and age-related diseases. The company was founded by Jean-Yves Bonnefoy, Christopher Henderson, Thierry Noel, Olivier Pourquié, Marie Knockaert and Jérôme Chal on April 25, 2011 and is headquartered in Graffenstaden, France.

Emosis SAS engages in research and experimental development on natural science and engineering. It addresses the unmet testing needs of patients presenting a broad range of conditions, such as cardiovascular and cerebrovascular diseases, cancer, pregnancy or surgical complications and complication of oral contraceptives, associated with bleeding and blood clotting disorders hemostasis and thrombosis in medical parlance. The company was founded by Aaron Tomer and Frederic Allemand in 2015 and is headquartered in Illikirch-Graffenstaden, France.

Capital Grand Est SAS (Capital Grand Est) formerly known as Alsace Capital, is a private equity firm headquartered in France. Founded in 2012, the firm is wholly owned by Region Grand Est of France and has offices in Schiltigheim, France.

Capital Grand Est SAS (Capital Grand Est) formerly known as Alsace Capital, is a private equity firm headquartered in France. Founded in 2012, the firm is wholly owned by Region Grand Est of France and has offices in Schiltigheim, France.

Emosis SAS engages in research and experimental development on natural science and engineering. It addresses the unmet testing needs of patients presenting a broad range of conditions, such as cardiovascular and cerebrovascular diseases, cancer, pregnancy or surgical complications and complication of oral contraceptives, associated with bleeding and blood clotting disorders hemostasis and thrombosis in medical parlance. The company was founded by Aaron Tomer and Frederic Allemand in 2015 and is headquartered in Illikirch-Graffenstaden, France.

Anagenesis Biotechnologies SAS operates as a preclinical-stage stem cell-based company. It focuses on developing novel treatments for genetic and age-related muscle degenerative diseases with unmet medical needs. The firm offers cell therapy for genetic diseases and pharmacological drugs for genetic and age-related diseases. The company was founded by Jean-Yves Bonnefoy, Christopher Henderson, Thierry Noel, Olivier Pourquié, Marie Knockaert and Jérôme Chal on April 25, 2011 and is headquartered in Graffenstaden, France.

Anagenesis Biotechnologies SAS operates as a preclinical-stage stem cell-based company. It focuses on developing novel treatments for genetic and age-related muscle degenerative diseases with unmet medical needs. The firm offers cell therapy for genetic diseases and pharmacological drugs for genetic and age-related diseases. The company was founded by Jean-Yves Bonnefoy, Christopher Henderson, Thierry Noel, Olivier Pourquié, Marie Knockaert and Jérôme Chal on April 25, 2011 and is headquartered in Graffenstaden, France.

Emosis SAS engages in research and experimental development on natural science and engineering. It addresses the unmet testing needs of patients presenting a broad range of conditions, such as cardiovascular and cerebrovascular diseases, cancer, pregnancy or surgical complications and complication of oral contraceptives, associated with bleeding and blood clotting disorders hemostasis and thrombosis in medical parlance. The company was founded by Aaron Tomer and Frederic Allemand in 2015 and is headquartered in Illikirch-Graffenstaden, France.

Urania Therapeutics SAS develops therapeutic solutions for the treatment of genetic diseases caused by pathogenic nonsense mutations. The company was founded by Jean-Paul Renaud, Marat Yusupova, and Gulnara Yusupova in October 2015 and is headquartered in Illkirc, France.

Capital Grand Est SAS (Capital Grand Est) formerly known as Alsace Capital, is a private equity firm headquartered in France. Founded in 2012, the firm is wholly owned by Region Grand Est of France and has offices in Schiltigheim, France.

Anagenesis Biotechnologies SAS operates as a preclinical-stage stem cell-based company. It focuses on developing novel treatments for genetic and age-related muscle degenerative diseases with unmet medical needs. The firm offers cell therapy for genetic diseases and pharmacological drugs for genetic and age-related diseases. The company was founded by Jean-Yves Bonnefoy, Christopher Henderson, Thierry Noel, Olivier Pourquié, Marie Knockaert and Jérôme Chal on April 25, 2011 and is headquartered in Graffenstaden, France.

Emosis SAS engages in research and experimental development on natural science and engineering. It addresses the unmet testing needs of patients presenting a broad range of conditions, such as cardiovascular and cerebrovascular diseases, cancer, pregnancy or surgical complications and complication of oral contraceptives, associated with bleeding and blood clotting disorders hemostasis and thrombosis in medical parlance. The company was founded by Aaron Tomer and Frederic Allemand in 2015 and is headquartered in Illikirch-Graffenstaden, France.

Anagenesis Biotechnologies SAS operates as a preclinical-stage stem cell-based company. It focuses on developing novel treatments for genetic and age-related muscle degenerative diseases with unmet medical needs. The firm offers cell therapy for genetic diseases and pharmacological drugs for genetic and age-related diseases. The company was founded by Jean-Yves Bonnefoy, Christopher Henderson, Thierry Noel, Olivier Pourquié, Marie Knockaert and Jérôme Chal on April 25, 2011 and is headquartered in Graffenstaden, France.

Anagenesis Biotechnologies SAS operates as a preclinical-stage stem cell-based company. It focuses on developing novel treatments for genetic and age-related muscle degenerative diseases with unmet medical needs. The firm offers cell therapy for genetic diseases and pharmacological drugs for genetic and age-related diseases. The company was founded by Jean-Yves Bonnefoy, Christopher Henderson, Thierry Noel, Olivier Pourquié, Marie Knockaert and Jérôme Chal on April 25, 2011 and is headquartered in Graffenstaden, France.

Capital Grand Est SAS (Capital Grand Est) formerly known as Alsace Capital, is a private equity firm headquartered in France. Founded in 2012, the firm is wholly owned by Region Grand Est of France and has offices in Schiltigheim, France.

Emosis SAS engages in research and experimental development on natural science and engineering. It addresses the unmet testing needs of patients presenting a broad range of conditions, such as cardiovascular and cerebrovascular diseases, cancer, pregnancy or surgical complications and complication of oral contraceptives, associated with bleeding and blood clotting disorders hemostasis and thrombosis in medical parlance. The company was founded by Aaron Tomer and Frederic Allemand in 2015 and is headquartered in Illikirch-Graffenstaden, France.

Capital Grand Est SAS (Capital Grand Est) formerly known as Alsace Capital, is a private equity firm headquartered in France. Founded in 2012, the firm is wholly owned by Region Grand Est of France and has offices in Schiltigheim, France.

Urania Therapeutics SAS develops therapeutic solutions for the treatment of genetic diseases caused by pathogenic nonsense mutations. The company was founded by Jean-Paul Renaud, Marat Yusupova, and Gulnara Yusupova in October 2015 and is headquartered in Illkirc, France.

Capital Grand Est SAS (Capital Grand Est) formerly known as Alsace Capital, is a private equity firm headquartered in France. Founded in 2012, the firm is wholly owned by Region Grand Est of France and has offices in Schiltigheim, France.